

Drugs and Aging, 2019

Supplement: Safety of Anti-Osteoarthritis Medications

Safety of opioids in osteoarthritis: Outcomes of a systematic review and meta-analysis

Nicholas Fuggle, Elizabeth Curtis, Sarah Shaw, Laura Spooner, Olivier Bruyère, Georgia Ntani, Camille Parsons, Philip G. Conaghan, Nadia Corp, Germain Honvo, Daniel Uebelhart, Janis Baird, Elaine Dennison, Jean-Yves Reginster, Cyrus Cooper

ELECTRONIC SUPPLEMENTARY MATERIAL 2

Figure 1 Relative risk (RR) of lower gastrointestinal (GI) symptoms for immediate release opioids versus placebo




Figure 2 Relative risk (RR) of nausea/vomiting/loss of appetite for immediate release opioids versus placebo

Opioids (immediate release) vs Placebo




Figure 3 Relative risk (RR) of dry mouth/oral ulcers for immediate release opioids versus placebo





Figure 4 Relative risk (RR) of central nervous system (CNS) adverse events (AEs) for immediate release opioids versus placebo

Opioids (immediate release) vs Placebo



NOTE: Weights are from random effects analysis

Risk ratio
CNS adverse events

Figure 5 Relative risk (RR) of rash/pruritus for immediate release opioids versus placebo

Opioids (immediate release) vs Placebo




Figure 6 Relative risk (RR) of lower GI symptoms for extended release opioids versus placebo

Opioids (extended release) vs Placebo





Figure 7 Relative risk (RR) of nausea/vomiting/loss of appetite for extended release opioids versus placebo

Opioids (extended release) vs Placebo



NOTE: Weights are from random effects analysis

Risk ratio
Nausea or vomiting, loss of appetite

Figure 8 Relative risk (RR) of dry mouth/oral ulceration for extended release opioids versus placebo





Figure 9 Relative risk (RR) of central nervous system (CNS) adverse events for extended release opioids versus placebo

Opioids (extended release) vs Placebo



NOTE: Weights are from random effects analysis

Risk ratio
CNS adverse events

Figure 10 Relative risk (RR) of upper GI symptoms for extended release opioids versus placebo




Figure 11 Relative risk (RR) of rash/pruritus for extended release opioids versus placebo

Opioids (extended release) vs Placebo




Figure 12 Relative risk (RR) of total adverse events for extended release opioids versus placebo

